Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT and rhGM-CSF in Stage IV NSCLC
NCT02623595Phase 2Withdrawn
- Sponsor
- Wuhan University
- Start
- May 2016
- Primary completion
- May 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of sargramostim in non-small cell lung cancer (NSCLC), sponsored by Wuhan University. Planned start May 2016; status: withdrawn.
02
Drugs
sargramostim
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02623595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02623595.